Now live at #AACR26 — join Sam Lawn for “ZW191 – a differentiated FRα-targeted topoisomerase I antibody-drug conjugate active in combinat...

Zymeworks Inc.· @ZymeworksInc · X·2026-04-21 00:00· 2026-04-21Score60

Body

Now live at #AACR26 — join Sam Lawn for “ZW191 – a differentiated FRα-targeted topoisomerase I antibody-drug conjugate active in combination with standard-of-care therapies.”

If you’re onsite, stop by Poster Board 4 in Poster Section 13 between 9:00 am - 12:00 pm PT to connect

Heat 1 · 1 like · 0 replies · 0 reposts

Conference abstracts

CT306NCT06555744matched by 代号 ZW191

Phase 1 first-in-human multicenter open-label study of ZW191, a folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors: Part 1 dose-escalation results

Patricia LoRusso, David Sommerhalder, Kosei Hasegawa, Kenichi Harano, David S. Tan, Noboru Yamamoto, David M. O’Malley, Kathleen N. Moore, Sarah E. Church, Lin Lu, Sabeen Mekan, Pranshul Chauha, Jung-Yun Lee

Read the abstract →

Source: Zymeworks Inc. · x.com